Prelude Therapeutics (NASDAQ: PRLD) net income
Prelude Therapeutics reported a net loss of $99.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $127.2m. Earnings per share were −$1.29.
Prelude Therapeutics's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$99.5m | — | −819.6% | −$1.29 |
| 2024 | −$127.2m | — | −1,816.8% | −$1.68 |
| 2023 | −$121.8m | — | — | −$2.02 |
| 2022 | −$115.4m | — | — | −$2.44 |
| 2021 | −$111.7m | — | — | −$2.43 |
| 2020 | −$56.9m | — | — | — |
| 2019 | −$27.6m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Prelude Therapeutics net income compared with its sector
By net income for its latest fiscal year, Prelude Therapeutics ranks 332nd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Prelude Therapeutics, −819.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 330th | PROCEPT BioRobotics | −$95.6m | −31.0% |
| 331st | AMN Healthcare Services | −$95.7m | −3.5% |
| 332nd | Prelude Therapeutics | −$99.5m | −819.6% |
| 333rd | Lexeo Therapeutics | −$100.0m | — |
| 334th | Tango Therapeutics | −$101.6m | −162.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Prelude Therapeutics
- How much did Prelude Therapeutics earn in fiscal 2025?
- Prelude Therapeutics reported a net loss of $99.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $127.2m.
- What are the earnings per share of Prelude Therapeutics?
- They were −$1.29 in fiscal 2025, compared with −$1.68 in fiscal 2024.
- Where does Prelude Therapeutics rank in its sector by net income?
- It ranks 332nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Prelude Therapeutics come from?
- From the annual report (Form 10-K) that Prelude Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Prelude Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Prelude Therapeutics: the Prelude Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.